InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
2
T+90 hit rate
67%
T+90 mean return
+20.8%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by COELHO PHILIP H, Director. Director active across 2 companies, notably Ampio Pharmaceuticals, Inc.. In total, 13 disclosures have been recorded. Split: 0 buy · 2 sells. Total volume traded: €1.2m. Activity tracked since 21 May 2021. The latest transaction was filed on 4 May 2023 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations13 total
50,000 shares@ US$0.792.5% of flowCommon stock, par value $0.001 per shareSEC:0001161697-23-000283:0
4,000 sharesCommon stock, par value $0.001 per shareSEC:0001161697-23-000123:0
1,334 sharesCommon stock, par value $0.001 per shareSEC:0001161697-22-000569:0
70,000 shares@ US$15.23173.0% of flowCommon stock, par value $0.001 per shareSEC:0001161697-22-000560:0
10,000 shares@ US$15.7011.1% of flowCommon stock, par value $0.001 per shareSEC:0001161697-22-000455:0
40,000 shares@ US$2.537.0% of flowCommon stock, par value $0.001 per shareSEC:0001161697-22-000397:0
1,333 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-21-000549
1,333 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-21-000549:0
16,667 shares@ US$3.123.1% of flowCommon stock, par value $0.001 per shareSEC:0001161697-21-000408
16,667 shares@ US$3.120.0012% mcap50.0% of flowCommon stock, par value $0.001 per shareSEC:0001161697-21-000408:0
6,737 shares@ US$0.401.06% mcap50.0% of flowCommon StockSEC:0001415889-21-002666:0
6,737 shares@ US$0.4050.0% of flowCommon StockSEC:0001415889-21-002666
6,042 sharesCommon StockSEC:0001209191-16-090074:0
13 of 13 declarations
About COELHO PHILIP H
Philip H. Coelho is a Board Member at Ampio Pharmaceuticals, Inc. and CATALYST PHARMACEUTICALS, INC. In this role, he contributes to corporate governance and strategic decision-making. Philip H. Coelho brings his expertise in biopharmaceuticals, enabling him to guide the board in achieving the company's objectives. His commitment to innovation and quality is essential for the company's development.
